<DOC>
	<DOC>NCT02515838</DOC>
	<brief_summary>A Multi-Centre, Phase II, Randomized, Double-Blind, Placebo-Controlled Study to investigate Efficacy and Safety of Sevuparin Infusion for the Management of Acute Vaso-Occlusive Crisis (VOC) in Subjects with Sickle-Cell Disease (SCD).</brief_summary>
	<brief_title>Sevuparin Infusion for the Management of Acute VOC in Subjects With SCD</brief_title>
	<detailed_description>This will be a phase II, multi-centre, randomized, double-blind, placebo-controlled study designed to assess preliminary efficacy, safety and pharmacokinetics (PK) of 2-7 days continuous IV administration of sevuparin for the management of acute VOC in subjects with SCD. Adults and adolescents ≥ 12 years of age will be randomized to treatment with sevuparin or placebo (ratio 1:1).</detailed_description>
	<mesh_term>Anemia, Sickle Cell</mesh_term>
	<criteria>Sign a written informed consent (adults, parents) and assent (adolescents) Male or female, age 1250 years. Diagnosis of Sickle cell disease Subjects admitted for an acute, painful VOC to be treated/or treated with parenteral opioid analgesia. Expectancy of need for hospitalization during at least 48 hours. Be at least 1 year postmenopausal, surgically sterile, or if Women of Child Bearing Potential (WOCBP), e.g. following menarche practicing an effective method of birth control Severe hepatic failure/disease, abnormal liver enzyme tests or history of hepatitis B virus (HBV), hepatitis C virus (HCV) Abnormal conjugated (direct) bilirubin 3 fold above ULN History of clinically significant bleeding in vital organs Current clinically significant bleeding, as judged by the investigator Current use of acetylsalicylic acid (ASA), antiplatelet therapy, anticoagulant therapy Abnormal coagulation laboratory values A platelet count &lt;75,000/µL. BMI &gt;35 Subjects with more than 5 hospitalizations for VOC during the last 6 months Evidence of acute SCD complications other than VOC at screening The use of strong opioids for &gt; 3 consecutive days during the last 15 days before presenting to the hospital History of chronic drug abuse. Renal dysfunction Known infection (positivity) with human immunodeficiency virus (HIV), HBV or HCV. Significant ECG abnormality History of a clinically significant drug allergy to heparin, LMWH's, sevuparin, or morphine. Use of any investigational agent during the 30 days prior to the first dose. For females: pregnancy, lactating or intention of becoming pregnant Evidence of clinically significant disorders that might interfere with the study aim or safety of the subject Any condition that, in the view of the Investigator, places the subject at high risk of poor treatment compliance or of not completing the study.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>